All the Re-Registration applications of Salofalk? preparations agented by Shenzhen Kangzhe Pharmaceutical Co Ltd. have been approved by CFDA, including Salofalk? Suppositories, Salofalk? Enteric-coated Tablets and Salofalk? Enemas. Recently, Regulatory Affairs Department of CMS has achieved the Imported Drug License for a new strength of Salofalk? Suppositories, which adds a new member to Salofalk? product group and enriches the product portfolio of the company. Salofalk? preparations can be used to treat inflammatory bowel disease (IBD), including Ulcerative colitis(UC) and Crohn’s disease(CD).